Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sintilimab + Chemotherapy for Esophageal Cancer
NCT04625543Phase 2Withdrawn
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Qilu Hospital of Shandong University. Planned start Dec 2020; status: withdrawn.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04625543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625543.